Talus Bio

Talus Bio is developing drugs for incurable childhood cancers. These cancers are nearly always caused by dysfunction in genome regulation, and Talus Bio has built a drug development platform using next-gen proteomics and AI to find new drugs for more than 400 presently untreatable genome regulators that play a role in

Talus Bio is active in the nfx portfolio space based in Seattle, WA, USA, founded in 2020.

Profile

We have built a platform that enables drug discovery and development for previously undruggable genome regulators ("the regulome"). We accomplish this by moving drug discovery out of artificial systems where regulome proteins fail to function properly, and back into live human cells. Our technology combines innovations in automated cell processing, next-gen proteomics, and advanced data analytics to measure a drug's effect on the entire regulome in one experiment.

Its activity falls under nfx portfolio; the profile below is assembled from public directory data.

The company is recorded as being based in Seattle, WA, USA.

Directory data places it at the Summer 2021 stage.

The company reports a headcount in the 16 range.

Website: www.talus.bio